Secondary Strongyloides stercoralis prophylaxis in patients with human T-cell lymphotropic virus type 1 infection: report of two cases

International Journal of Infectious Diseases

Volumn 13, Issue 6, 2009, Pages

  Peters, Laurenna ^a   McCarthy, Anne E ^b   Faught, Carolyn ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Disseminated strongyloidiasis; HTLV 1 associated malignancy; Hyperinfection; Ivermectin secondary prophylaxis; Strongyloides

Indexed keywords

ANTIINFECTIVE AGENT; IVERMECTIN; TIABENDAZOLE;

ADULT; ARTICLE; BACTERIAL MENINGITIS; CANCER CHEMOTHERAPY; CASE REPORT; DIARRHEA; DRUG WITHDRAWAL; ENDOCARDITIS; ESCHERICHIA COLI; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; GIARDIASIS; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HOSPITAL DISCHARGE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMIGRANT; INAPPROPRIATE VASOPRESSIN SECRETION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PNEUMONIA; REMISSION; RISK FACTOR; SECONDARY PREVENTION; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; T CELL LEUKEMIA; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; VOMITING;

ADULT; ANIMALS; ANTINEMATODAL AGENTS; CHEMOPREVENTION; FATAL OUTCOME; FEMALE; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IVERMECTIN; LEUKEMIA, T-CELL; LYMPHOMA, NON-HODGKIN; MALE; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS;

EID: 70350571249     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.02.009     Document Type: Article

References (18)

1. Hauber H.P., Galle J., Chiodini P.L., Rupp J., Birke R., Vollmer E., et al. Fatal outcome of a hyperinfection syndrome despite successful eradication of Strongyloides with subcutaneous ivermectin. Infection 33 (2005) 383-386
2. Igra-Siegman Y., Kapila R., Sen P., Zigmund C., Kaminski C., and Louria D.B. Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis 3 (1981) 397-407
3. Lam C.S., Tong M.K., Chan K.M., and Siu Y.P. Disseminated strongyloidiasis: a retrospective study of clinical course and outcome. Eur J Clin Microbiol Infect Dis 25 (2006) 14-18
4. Lim S., Katz K., Krajden S., Fuksa M., Keystone J.S., and Kayne K.C. Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management. CMAJ 171 (2004) 479-484
5. Patel G., Arvelakis A., Sauter B.V., Gondolesi G.E., Caplivski D., and Huprikar S. Strongyloides hyperinfection syndrome after intestinal transplantation. Transpl Infect Dis 10 (2008) 137-141
6. Keiser P.B., and Nutman T.B. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev 17 (2004) 208-217
7. Salluh J.I., Bozza F.A., Pinto T.S., Toscano L., Weller P.F., and Soares M. Cutaneous periumbilical purpura in disseminated strongyloidiasis in cancer patients: a pathognomonic feature of potentially lethal disease?. Braz J Infect Dis 9 (2005) 419-424
8. Hayashi J., Kishihara Y., Yoshimura E., Furusyo N., Yamaji K., Kawakami Y., et al. Correlation between human T cell lymphotropic virus type-1 and Strongyloides stercoralis infections and serum immunoglobulin E responses in residents of Okinawa, Japan. Am J Trop Med Hyg 56 (1997) 71-75
9. Gotuzzo E., Terashima A., Alvarez H., Tello R., Infante R., Watts D.M., et al. Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru. Am J Trop Med Hyg 60 (1999) 146-149
10. Satoh M., Toma H., Sato Y., Takara M., Shiroma Y., Kiyuna S., et al. Reduced efficacy of treatment of strongyloidiasis in HTLV-I carriers related to enhanced expression of IFN-γ and TGF-β1. Clin Exp Immunol 127 (2002) 354-359
11. Higashiyama Y., Sakata H., Obase Y., Sakata S., Shimafuji T., Mori M., et al. [A case of bacterial meningitis induced by strongyloidiasis]. Kansenshogaku Zasshi 71 (1997) 680-683
12. Mitsunaga M., Miyauchi N., Akiyama Y., and Saima S. [A case of strongyloidiasis hyperinfection during oral corticosteroid therapy associated with a nephritic patient infected with HTLV-1]. Nippon Ronen Igakkai Zasshi 40 (2003) 397-401
13. Sato Y., Kobayashi J., Toma H., and Shiroma Y. Efficacy of stool examination for detection of Strongyloides infection. Am J Trop Med Hyg 53 (1995) 248-250
14. Kobayashi J., Sato Y., Toma H., Takara M., and Shiroma Y. Application of enzyme immunoassay for post chemotherapy evaluation of human strongyloidiasis. Diagn Microbiol Infect Dis 18 (1994) 19-23
15. Loutfy M.R., Wilson M., Keystone J.S., and Kain K.C. Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area. Am J Trop Med Hyg 66 (2002) 749-752
16. Page W.A., Dempsey K., and McCarthy J.S. Utility of serological follow-up of chronic strongyloidiasis after anthelminthic chemotherapy. Trans R Soc Trop Med Hyg 100 (2006) 1056-1062
17. Marti H., Haji H.J., Savioli L., Chwaya H.M., Mgeni A.F., Ameir J.S., et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg 55 (1996) 477-481
18. Drugs for parasitic infections. The Medical Letter. 2007; 5e1-15.